News – Page 906 – Endpoints News

Under new leadership, Novartis' Sandoz unit breaks up with digital therapeutics outfit Pear

6 years ago

Alexion pays $930M to buy out Achillion and its promising companion drug to Soliris

6 years ago

Months after $10M Series A, rare disease AI upstart Healx hauls in $56M in fresh funding

6 years ago

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

6 years ago

Can CBD temper Parkinson's-related psychosis? UK researchers will look for answers in PhII study

6 years ago

Floating in stormy seas, RTW seeks $350M for new London-listed venture fund

6 years ago

Gilead's chief strategy exec gets a big promotion after orchestrating multibillion-dollar deals

6 years ago

Checkmate Pharmaceuticals brings two new execs on board; Takeda sheds 30 drugs, gains $200M in Acino deal

6 years ago

Gilead vet Alessandro Riva steers Glenmark's biotech spinoff on independent course

6 years ago

That big neurosciences R&D group Eli Lilly built is being dismantled, with layoffs and parts shipped home

6 years ago

Cyteir nets $40M for rad synthetic lethality platform — throwing another monkey wrench at cell repair

6 years ago

Patient experience data: Sanofi researchers call for more consistency from FDA

6 years ago

Woodford fired from flagship fund — which won't reopen after all

6 years ago

Surprising Wall Street, Reata unveils positive pivotal data on Friedreich’s ataxia drug

6 years ago

Boehringer Ingelheim-backed Abalos tosses hat into packed oncolytic virus ring

6 years ago

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

6 years ago

US mulls tariffs on Swiss drug exports, weighing on Novartis and Roche – report

6 years ago

FDA requests additional time for Flexion's sNDA; Genentech releases data for PhIII study of Rituxan

6 years ago

BridgeBio drops bid to reclaim Eidos after directors spurn 3 offers

6 years ago

HR violation pushes Revance co-founder out, vaulting former Zeltiq chief to the helm

6 years ago

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

6 years ago

A predator's world? Top analyst sees the 'haves' and the 'haven'ts' diverge as biotech bubbles form — and collapse

6 years ago

Cell therapy startup raises $16 million to fund its quest for the Holy Grail in regenerative medicine

6 years ago

Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles

6 years ago

First page Previous page 903 904 905906907 908 909 Next page Last page